首页> 外文期刊>Clinical medicine: journal of the Royal College of Physicians of London >The emergence of sarcopenia as an important entity in older people
【24h】

The emergence of sarcopenia as an important entity in older people

机译:SARCOPENIA作为老年人的重要实体出现

获取原文
获取原文并翻译 | 示例
           

摘要

Sarcopenia refers to the loss of muscle mass and strength seen with advancing age. The pathophysiology is multifactorial, with loss of muscle satellite cells, changes in hormonal systems, chronic inflammation, oxidative stress and anabolic resistance to protein utilisation all implicated. Older age, female sex and immobility are important risk factors. Sarcopenia is clinically important as it is a major risk factor for physical frailty, falls, prolonged hospitalisation, dependency and earlier death. Diagnosis requires evidence of reduced muscle mass measured by handgrip strength or walk speed, together with evidence of low muscle mass, measured by one of a variety of techniques such as bioimpedance analysis or dual X-ray absorptiometry. Resistance training is the only intervention of proven efficacy to treat sarcopenia, but a range of nutritional and pharmacological interventions are under test, including myostatin inhibitors, leucine and protein supplementation, angiotensin converting enzyme inhibitors and allopurinol.
机译:Sarcopenia是指肌肉肿块和前进时期的力量的丧失。病理生理学是多因素,损失肌卫星细胞,激素系统的变化,慢性炎症,氧化应激和蛋白质利用的代谢性均无牵连。年龄较大,女性性和不动名是重要的风险因素。 Sarcopenia在临床上很重要,因为它是物理脆弱,瀑布,长期住院,依赖和早期死亡的主要危险因素。诊断需要通过手工强度或步行速度测量的肌肉质量减少的证据,以及低肌肉质量的证据,通过各种技术之一(例如生物阻抗分析或双X射线吸收测量)测量。抗性训练是治疗康迟腺的唯一疗效的干预,但营养和药理学干预措施都是试验,包括肌肉素抑制剂,亮氨酸和蛋白质补充剂,血管紧张素转化酶抑制剂和Allopurinol。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号